Objective The goal of this study is to compile published data reporting neurological immune-related adverse events following COVID-19 vaccination, not including those relating hematologic abnormalities such as thrombosis or hemorrhage. Background vaccination has been repeatedly shown reduce the incidence and severity infection. expedited timeline these vaccines given rise many discussions perta...

INTRODUCTION The peripheral nervous system is usually involved in the majority of systemic connective tissue diseases, particularly in systemic lupus erythematosus, Sjögren's syndrome, vasculitis and systemic sclerosis. The pathogenesis of lesions in the peripheral nervous system associated with the autoimmune process is complex and it appears that two mechanisms, immunological and ischemic, ar...

J.P. Cravens, K. Abe, T. Iida, K. Ishihara, J. Kameda, Y. Koshio, A. Minamino, C. Mitsuda, M. Miura, S. Moriyama, M. Nakahata, S. Nakayama, Y. Obayashi, H. Ogawa, H. Sekiya, M. Shiozawa, Y. Suzuki, A. Takeda, Y. Takeuchi, K. Ueshima, H. Watanabe, S. Yamada, I. Higuchi, C. Ishihara, M. Ishitsuka, T. Kajita, K. Kaneyuki, G. Mitsuka, H. Nishino, K. Okumura, C. Saji, Y. Takenaga, S. Clark, S. Desai...

M.B. Smy, Y. Ashie, S. Fukuda, Y. Fukuda, K. Ishihara, Y. Itow, Y. Koshio, A. Minamino, M. Miura, S. Moriyama, M. Nakahata, T. Namba, R. Nambu, Y. Obayashi, N. Sakurai, M. Shiozawa, Y. Suzuki, H. Takeuchi, Y. Takeuchi, S. Yamada, M. Ishitsuka, T. Kajita, K. Kaneyuki, S. Nakayama, A. Okada, T. Ooyabu, C. Saji, S. Desai, M. Earl, E. Kearns, M.D. Messier, J.L. Stone, L.R. Sulak, C.W. Walter, W. Wa...

Background and Aim: To determine the clinical outcome complications encountered in adult patients with acute viral hepatitis A (AVH-A). Methods: This is a retrospective analysis of prospectively maintained database consecutive AVH- /or E. The study period was between 2017 2022. Adult (>18 years) symptoms laboratory investigations suggestive illness were included. Patients associated B C infecti...

S. Desai, Y. Ashie, S. Fukuda, Y. Fukuda, K. Ishihara, Y. Itow, Y. Koshio, A. Minamino, M. Miura, S. Moriyama, M. Nakahata, T. Namba, R. Nambu, Y. Obayashi, N. Sakurai, M. Shiozawa, Y. Suzuki, H. Takeuchi, Y. Takeuchi, S. Yamada, M. Ishitsuka, T. Kajita, K. Kaneyuki, S. Nakayama, A. Okada, T. Ooyabu, C. Saji, M. Earl, E. Kearns, J.L. Stone, L.R. Sulak, C.W. Walter, W. Wang, M. Goldhaber, T. Bar...

F. Abe, H. Akimoto, A. Akopian, M. G. Albrow, A. Amadon, S. R. Amendolia, D. Amidei, J. Antos, S. Aota, G. Apollinari, T. Arisawa, T. Asakawa, W. Ashmanskas, M. Atac, P. Azzi-Bacchetta, N. Bacchetta, S. Bagdasarov, M. W. Bailey, P. de Barbaro, A. Barbaro-Galtieri, V. E. Barnes, B. A. Barnett, M. Barone, G. Bauer, T. Baumann, F. Bedeschi, S. Behrends, S. Belforte, G. Bellettini, J. Bellinger, D....

As currently designed, vaccineshave as their goal the conversion f a generally healthy but susceptible host, into a host protected gainst a disease (for which the vaccine is being administered) o which the host may be exposed to at a future date. To this nd, a high bar for effectiveness, efficacy, and safety of vaccines s appropriate. Interest in efficacy and safety is not confined to scintists...

Background. The Centers for Disease Control and Prevention (CDC) recommends adults born in 1957 or later have documentation of at least one dose of MMR vaccine and high risk adults and healthcare workers have a second dose. Limited data exists on the safety of MMR vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) in order to ass...

Nonetheless, despite these public health triumphs, vaccines can and do occasionally cause harm. For example, the widespread use of the polio vaccine resulted in vaccine-associated paralytic polio in 1 of every 2.4 million vaccine recipients. For this reason, calls for alternate schedules and cessation of the use of this vaccine began in the mid-1980s. 7 Indeed, the Advisory Committee on Immuniz...